More on KPTI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.79 |
|
|||
| Open | $1.77 | ||||
| 52 Wk High | $19.41 | ||||
| 52 Wk Low | $4.83 | ||||
| Day High | $1.79 | ||||
| Day Low | $1.70 | ||||
| P/E | N/A | ||||
| EPS | $-2.74 | ||||
| Volume | 1,007,322 | ||||
- Karyopharm files sNDA seeking FDA approval for myelofibrosis combo
- Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
- Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Commodore Capital LP
- Form 10-Q Karyopharm Therapeutics For: Jun 30
- Form 8-K Karyopharm Therapeutics For: Aug 13
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
- Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Adage Capital Management, L.P.
- Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: GOLDMAN SACHS GROUP INC
- Increasing unusual call volume: KPTI ACB SHLD ABAT BW PBF UPWK TME TENX BMBL ARMK AS KOPN SES
Entities mentioned with KPTI
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
